A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

Approximately 600 subjects will be enrolled in the study, of which at least 150 subjects aged 2-6; at least 140 subjects aged 7-11; at least 120 subjects aged 12-17 and up to 90 subjects will be adults. Subjects must have mild-moderate AD involving at least 5% treatable %BSA assessed on baseline/Day 1. Treatable %BSA will be defined as the percent of a subject's total body surface area that is AD involved, excluding the scalp.

Eligible subjects will be randomized at the Baseline/Day 1 visit. Randomization will be stratified by eligibility for TCS or TCI treatment as per national approved labels. Cohort 1 will be for subjects who are eligible for TCS therapy, and Cohort 2 will be for subjects who are not eligible for TCS therapy but eligible for TCI therapy. The investigational products will be applied BID for 28 days to the Treatable body surface area (BSA) identified at Baseline/Day 1.

The primary efficacy endpoint is the percent change from baseline in the Eczema Area and Severity Index (EASI) total score at Day 29.

For the efficacy comparison of crisaborole versus vehicle, subjects from both Cohort 1 and Cohort 2 are included in the analysis, adjusted for cohort effect. For the efficacy comparison of crisaborole versus TCS, only subjects from Cohort 1 are included in the analysis. For the comparison of crisaborole versus TCI, only subjects from Cohort 2 are included in the analysis.

Safety and efficacy assessments will be conducted at the investigator site by a clinical assessor blinded to treatment assignment.

Scheduled study visits for all subjects will occur at Screening, Baseline/Day 1, Day 8, Day 15, Day 22, Day 29 (End of treatment/Early termination). A follow up telephone call will be made by site staff to the subjects/subject's legally acceptable guardian(s) on Day 36 and Day 60.

Primary Purpose: Treatment

• Drug: Crisaborole ointment, 2%
  
  Applied twice a day (BID)
  Other Name: Eucrisa
• Drug: Hydrocortisone butyrate cream, 0.1%
  
  Applied BID
  Other Name: Locoid 0.1%
• Drug: Pimecrolimus cream, 1%
  
  Applied BID
  Other Name: Elidel
• Drug: Crisaborole Vehicle
  
  Applied BID

• Experimental: Crisaborole ointment, 2%
  
  This treatment arm will be administered both in Cohort 1 and Cohort 2.
  Intervention: Drug: Crisaborole ointment, 2%
• Active Comparator: Hydrocortisone butyrate cream, 0.1%
  
  This treatment arm will be administered in Cohort 1 only.
  Intervention: Drug: Hydrocortisone butyrate cream, 0.1%
• Active Comparator: Pimecrolimus cream, 1%
  
  This treatment arm will be administered in Cohort 2 only.
  Intervention: Drug: Pimecrolimus cream, 1%
• Placebo Comparator: Crisaborole Vehicle
  
  This treatment arm will be administered both in Cohort 1 and Cohort 2.
  Intervention: Drug: Crisaborole Vehicle

Inclusion Criteria:

Is male or female 2 years and older at the Screening visit/time of informed consent/assent diagnosed with mild-moderate AD (according to the criteria of Hanifin and Rajka), of at least 5% BSA.

Exclusion Criteria:

Has any clinically significant medical disorder, condition, or disease (including active or potentially recurrent non AD dermatological conditions and known genetic dermatological conditions that overlap with AD, such as Netherton syndrome.

Subjects in Cohort 1 are excluded if they have a contraindication for treatment with hydrocortisone butyrate cream 0.1%

Subjects in Cohort 2 are excluded if they have a contraindication for treatment with pimecrolimus cream, 1%